ATS 2019 Virtual Final Program

P303 Cellular Consequences of Uncharacterized Surfactant Protein-A2 (SFTPA2)-Gene Mutations Associated with Familial Idiopathic Pulmonary Fibrosis (IPF) and Lung Cancer/ M. Korfei, K. Guenther, W. Seeger, A. Guenther, Giessen, Germany, p.A7407 BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION C59 GENETIC AND EPIGENETIC MECHANISMS IN PULMONARY FIBROSIS 9:15 a.m. - 4:15 p.m. KBHCCD Area C (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : B.R. Gochuico, MD, Bethesda, MD P305 Frequency of Single Nucleotide Polymorphisms of Five Genes in Idiopathic Pulmonary Fibrosis Patients Treated with Pirfenidone/ W.H. Amundson, A. Lee, J.R. Bishop, H.J. Kim, Minneapolis, MN, p.A5260 P306 Analysis of Polymorphism in ATG16L1 Gene and the Risk to Idiopathic Pulmonary Fibrosis/ L. Laguna, I. Buendia-Roldan, N. Zavala Partida, S. Cabrera, J. Castillo, G. Perez-Rubio, R. Falfan-Valencia, Mexico City, Mexico, p.A5261 P307 Alveolar and Fibroblast Foci Specific Genome-Wide Gene Expression Profiling Identifies Common Dysregulated Expression of CREB1, a Regulator Across Cell Types, in IPF/ M. Vukmirovic, C. Brereton, X. Yan, N. Xylourgidis, G. Deluliis, T. Woolard, B. Hu, A. Mihaljinec, R. Homer, J.H. Maya, F. Ahangari, A. Fabre, D. Smart, F. Conforti, B.J. Marshall, A. Alzetani, D.E. Davies, L. Richeldi, N. Kaminski, M.G. Jones, New Haven,, p.A5262 P308 Functional Analysis of Lung Disease-Associated SNPs Using Genome-Editing Tools/ Y. Maeda, W. Stuart, I. Fink-Baldauf, J. Brewington, J.P. Clancy, Cincinnati, OH, p.A5263 P309 Whole Genome Sequencing of Patients with Pulmonary Fibrosis/ R. Sutton, M. Roth, R. Grubs, Y. Zhang, R. Stewart, H. Si, S. Mentch, A. Berndt, J.F. McDyer, D. Kass, J.K. Alder, Pittsburgh, PA, p.A5264 P310 Epigenetic Age Acceleration in Idiopathic Pulmonary Fibrosis/ D. Kurbanov, F. Ahangari, N. Xylourgidis, J.E. McDonough, W. Wuyts, B.M. Vanaudenaerde, M. Levine, N. Kaminski, New Haven, CT, p.A5265 P311 The Differential Effects of Hermansky-Pudlak Syndrome 1 and 2 on Lung Fibroblast Behavior/ K. Cuevas Mora, D. Sales, H. Shaghaghi, R.S. Summer, F. Romero, Philadelphia, PA, p.A5266 P312 Shortened Telomeres in Type II Alveolar Epithelial Cells in Hermansky-Pudlak Syndrome Pulmonary Fibrosis/ B.R. Gochuico, H. Dorward, T. Franklin, K. O’Brien, W. Gahl, M.C.V. Malicdan, C. Han, Bethesda, MD, p.A5267 P313 Alveolar Epithelial Type 2 Cell Dysfunction in Hermansky-Pudlak Syndrome Type 2 Patient-Derived Induced Pluripotent Stem Cells/ Y. Korogi, S. Gotoh, S. Ikeo, Y. Yamamoto, N. Sone, K. Tamai, S. Konishi, T. Nagasaki, I. Asaka, A. Hotta, T. Hirai, Kyoto, Japan, p.A5268 Facilitator : P.A. Reyfman, MD, Chicago, IL P314 A Therapeutic Approach for Idiopathic Pulmonary Fibrosis (IPF) by Targeting miR-96/ R. Nho, J. Im, Minneapolis, MN, p.A5269 P315 Expression Analysis of Serum microRNAs in Acute Exacerbation of Idiopathic Pulmonary Fibrosis/ K. Oda, H. Izumi, M. Tahara, Y. Morimoto, H. Mukae, K. Yatera, Fukuoka, Japan, p.A5270 P316 microRNA Machinery Is Dysregulated in Fibroblasts of Patients with Pulmonary Fibrosis/ A.R. Rackow, R.M. Kottmann, C. Woeller, T.H. Thatcher, P.J. Sime, Rochester, NY, p.A5271 P317 Fibrocyte-Derived Exosomes Contain Profibrotic miRNAs Consistent with Serum miRNAs from Patients with Idiopathic Pulmonary Fibrosis/ S.G. Chong, P. Nadarajan, A. Fabre, M.P. Keane, Dublin, Ireland, p.A5272 P318 Expression of Pro-Fibrotic microRNA of Fibrocytes in Bronchoalveolar Lavage Fluid/ S. Sato, C.B. Upagupta, T. Yanagihara, M.R.J. Kolb, Y. Nishioka, Tokushima, Japan, p.A5273 P319 Loss of lncRNA FENDRR Induces Senescence in Adult Mouse Lungs/ N. Xylourgidis, K. Sakamoto, J.C. Schupp, T. Adams, G. DeIuliis, N. Omote, N. Hashimoto, Y. Hasegawa, N. Kaminski, New Haven, CT, p.A5274 P320 The Role of Histone Methyltransferase EZH2 in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis/ S. Okamori, M. Ishii, S. Suzuki, T. Kusumoto, T. Ogawa, M. So, H. Kamata, T. Asakura, S. Kagawa, T. Betsuyaku, Tokyo, Japan, p.A5275 P321 Disease Specific Upregulation of Protein Arginine Methyltransferases in IPF/ C. Lambers, S. Blumer, F. Lei, A. Benazzo, K. Hoetzenecker, P. Jaksch, M. Tamm, M. Roth, Vienna, Austria, p.A5276 P322 The mTOR Pathway Genes Are Differentially Methylated in African- and Hispanic- Americans Who Fail to Survive Acute Respiratory Distress Syndrome (ARDS)/ H. Lynn, N.G. Casanova, D. Coletta, C. Bime, M. Gonzales Ganay, X. Sun, J.G.N. Garcia, Tucson, AZ, p.A5277 P323 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis/ R. Montgomery, S. Roy, K. Rigby, A. Jackson, P. Rubin, Boulder, CO, p.A7408 P324 Pulmonary Surfactant Protein A2 Polymorphism rs1965708 Associates with Upper Airway Disease Prevalence/ G.T. Noutsios, A. Grozic, J.G. Ledford, A. Kim, W. Yoo, E.H. Chang, Phoenix, AZ, p.A7409 P325 Changes of Lung Transcriptome During Aging/ M.D.J. Calyeca, Y.I. Balderas-Martinez, M. Selman, A. Pardo, Mexico City, Mexico, p.A7410 ATS 2019 • Dallas, TX TUESDAY • MAY 21 273 TUESDAY MORNING